Medifocus Inc. Reports Improved Clinical Efficacy for its Phase II, Randomized Clinical Study for the Treatment of Large Breast Cancer Tumors



    VANCOUVER, April 8 /CNW/ - Medifocus Inc. (TSXV; MFS) announced that
positive clinical results, that demonstrate significant efficacy when using
the Company's proprietary focused heat treatment in combination with Standard
of Care (SOC) preoperative (neo-adjuvant) chemotherapy for large breast cancer
tumors, were presented during the Market Opening Ceremony of Medifocus at the
Toronto Stock Exchange on March 25, 2009 and also at the 19th National
Interdisciplinary Breast Center Conference held March 14-18, 2009 in Las
Vegas, Nevada., The patient data were obtained from a multi-center, randomized
clinical study to demonstrate improvement in tumor shrinkage when focused heat
is used in combination with SOC neo-adjuvant chemotherapy. This study was
conducted in the USA under an Investigational Device Exemption (IDE) issued by
the Food and Drug Administration (FDA).
    The reported clinical trial results demonstrated that when Medifocus's
focused heat therapy was added to the SOC neo-adjuvant chemotherapy in the
treatment of large breast cancer tumors, tumor shrinkage was increased by an
additional 50% over that induced by (SOC) chemotherapy alone. The median tumor
shrinkage in the Thermo-chemo arm was 88.4% and for the Chemotherapy alone
arm, the median tumor shrinkage was only 58.8%. This increase in median tumor
shrinkage was statistically significant with a P value equal to 0.048. In
addition, the data indicated that for the thermo-chemo treatment arm, almost
80% of all breast tumors treated had a tumor volume reduction of 80% or more
compared to only 20% for the chemotherapy alone.
    The treatment goal of the Medifocus study is to demonstrate that focused
heat treatment combined with SOC chemotherapy performed prior to surgery will
significantly lower the need for mastectomy and enhance the chance of
successful conversion to breast conserving surgery (BCS), a treatment outcome
desired by both the surgeons and breast cancer patients.

    About Medifocus

    Medifocus owns a patented microwave focusing technology (the Adaptive
Phased Array ("APA") technology), which can precisely target and control
microwave energy to cause heating in cancerous tumors anywhere in the body
reliably and repeatedly. The ability to target tumors with a precision
controlled dose of heat can be used to destroy tumors at higher temperatures,
to treat tumors in combination with chemotherapy and/or radiation at moderate
temperatures for increased effectiveness and reduced toxicity and to trigger
the targeted release of therapeutic drugs and genes at tumor sites at lower
temperatures. While the core technology has been licensed from the
Massachusetts Institute of Technology, Medifocus has further refined the
precision of the microwave focusing and control ability and developed a
commercial system dedicated exclusively for the treatment of Breast Cancer.
Please visit the company website at www.medifocusinc.com for more info.

    Forward Looking Statements and Information

    This News Release contains forward-looking statements which may not be
based on historical fact. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause the actual
results, events or developments to be materially different from any future
results, events or developments expressed or implied by such forward-looking
statements. These factors should be considered carefully and readers are
cautioned not to place undue reliance on such forward-looking statements. The
company disclaims any obligation to update any such factors or to publicly
announce the result of any revisions to any of the forward-looking statements
contained herein to reflect future results, events or developments.

    %SEDAR: 00023463E




For further information:

For further information: Jessie Song, NAI Interactive Ltd, (604)
488-8878/1-866-833-5517, jsong@na-investor.com; John Mon, Medifocus Inc.,
(410) 290-5734, jmon@medifocusinc.com

Organization Profile

MEDIFOCUS INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890